DAX21.962 +3,1%ESt505.099 +2,8%Top 10 Crypto12,46 +4,0%Dow39.607 +1,1%Nas16.708 +2,5%Bitcoin81.611 -1,2%Euro1,1341 +0,2%Öl66,21 +0,1%Gold3.326 +1,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Tesla A1CX3T NVIDIA 918422 Rheinmetall 703000 SAP 716460 RENK RENK73 Amazon 906866 Lufthansa 823212 Apple 865985 BYD A0M4W9 Mercedes-Benz Group (ex Daimler) 710000 Allianz 840400 BASF BASF11 Siemens Energy ENER6Y Volkswagen (VW) vz. 766403 Novo Nordisk A3EU6F
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zollstreit-Hoffnung: DAX schließt weit im Plus -- US-Börsen Handel endet fest -- Tesla mit Umsatz- und Gewinneinbruch -- SAP steigert Umsatz und Ergebnis -- NVIDIA, RENK, BYD, AMD, Xiaomi im Fokus
Top News
Jim Cramer: Turbulenzen am Aktienmarkt sind "künstlich geschaffen" Jim Cramer: Turbulenzen am Aktienmarkt sind "künstlich geschaffen"
Salesforce-Aktie zwischen Innovation und Risiko: Analysten streiten über KI-Strategie Salesforce-Aktie zwischen Innovation und Risiko: Analysten streiten über KI-Strategie
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Die Top 10 Coins im Depot - mit dem finanzen.net Top 10 Crypto ETP. Jetzt informieren!

Halozyme Therapeutics Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
51,22 EUR +0,34 EUR +0,67 %
STU
58,40 USD +0,21 USD +0,36 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.6,34 Mrd. EUR

KGV13,93Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0DLHS

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS40637H1095

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolHALO

Halozyme Therapeutics Aktien News

DatumMeistgelesen
PR NewswireHalozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinati...
PR NewswireEuropean Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
PR NewswireEuropean Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Wer­bungHalozyme Therapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireHalozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
PR NewswireHalozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
PR NewswireHALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
PR NewswireHalozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
PR NewswireCHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
PR NewswireHalozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
PR NewswireHalozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
PR NewswireHalozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
PR NewswireHalozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswireHalozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHalozyme nimmt Vorschlag über Zusammenschluss mit Evotec aufgrund fehlender Gesprächsbereitschaft von Evotec zurück
PR NewswireHalozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
PR NewswireHalozyme Provides Update on Non-Binding Proposal to Combine with Evotec
PR NewswireHalozyme bestätigt Vorschlag des Zusammenschlusses mit Evotec für 11,00 € pro Aktie im Rahmen eines Barangebots
PR NewswireHalozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction
PR NewswireHALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR NewswireHALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
PR NewswireHalozyme to Report Third Quarter 2024 Financial and Operating Results
PR NewswireHalozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
PR NewswireHalozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
PR NewswireHalozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
PR NewswireHalozyme to Present at Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR NewswireHalozyme to Report Second Quarter 2024 Financial and Operating Results
PR NewswireHalozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
PR NewswireHalozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
PR NewswireHalozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook
PR NewswireHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform
PR NewswireHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PR NewswireHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors
PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results
PR NewswireHalozyme to Participate in Upcoming Investor Conferences
PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
Wer­bung

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.